News Daiichi teams up with GAIA for cholesterol DTx in Europe Daiichi Sankyo has licensed European rights to GAIA's digital therapeutic for people with high cholesterol, currently in phase 3 testing.
News Orexo exits depression DTx alliance with GAIA Four years after buying US rights to GAIA's digital therapeutic to help people with depression, Swedish drugmaker Orexo has terminated the deal.
News Orexo buys US rights to GAIA's deprexis digital therapeutic Sweden's Orexo has announced it has bought the exclusive US rights to GAIA’s deprexis, a digital therapy to help patients manage their symptoms of depression and one of the most researched
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.